ARCHIVES

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

This article is from The Cancer Letter archive.

Vol. 13 No. 16 | April 17, 1987

Download PDF Visit The Full Archive

Related Articles

Tamoxifen Trial Enrolls 19% Of Women Needed, Fisher Reports To NCAB

October 16, 1992

Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response

November 29, 2013

NIH Funding Opportunity: Outstanding Investigator Award In Cancer Research Available

July 11, 2014

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

May 18, 2007

NCCS Networker Volume 10 Issue 1, Spring 1996

April 13, 1996

Starr Foundation Gives $100 Million To Form Cancer Consortium.

September 29, 2006